Thursday, 28 February 2019, 2112 Pennsylvania Avenue, NW Washington, DC 20037

GCR is delighted to host the inaugural GCR Live Pharmaceuticals event on Thursday, 28 February 2019, chaired by J. Mark Gidley, of White & Case and Christine Siegwarth Meyer, of NERA Economic Consulting. The conference is designed to create a forum for antitrust professionals in the pharmaceuticals sector to come together and hear from the leading names in the space. It promises to be an insightful conference for lawyers specialising in both defendant and plaintiff work, in-house practitioners, consultants, industry professionals and service providers. Topics for discussion include pricing cases and what they mean for the future of pharma; and the costs and pitfalls of innovation in the industry. The conference is expected to bring in audience members from across the US and internationally, allowing delegates to connect with and learn from like-minded individuals.

E-mail Tel: +44 20 3780 4137

Chairs

J. Mark Gidley

White & Case, Washington, DC

J. Mark Gidley chairs the White & Case global Antitrust/Competition Practice, which is the only such practice to have been named Competition Group of the Year for the past six years by Law360.  His practice focuses on mergers and acquisitions, cartel cases, class actions, and pharmaceutical antitrust cases, with an emphasis on trying antitrust cases.

Christine Siegwarth Meyer

NERA Economic Consulting, New York

Featured as one of Global Competition Review's "Women in Antitrust," Dr. Christine Meyer is considered one of the foremost testifying economists in the areas of complex commercial litigation involving intellectual property, antitrust claims, and commercial damages. In the area of intellectual property, Dr. Meyer has analyzed damages and provided expert testimony concerning issues arising from patent, trademark, and copyright infringement, the misappropriation of trade secrets, and breaches of contract. She has considerable expertise in analyzing lost profits, reasonable royalties, price erosion, commercial success, and irreparable harm.

Speakers

Kathleen Bradish

Cleary Gottlieb Steen & Hamilton, Washington, DC

Thomas Dillickrath

Deputy Chief Trial Counsel, Virginia

David Emanuelson

Global Antitrust Counsel, Intel, California

Christopher W. Healy

Reed Smith, New York

Kai-Uwe Kühn

Professor of Economics, University of East Anglia, Norwich

Chris Stomberg

NERA Economic Consulting, Washington, DC

Programme

Wednesday, 27 February

18.00 - 19.30: Drinks reception - Sponsored by White & Case

Thursday, 28 February

8.45: Welcome coffee and registration

9.15: Chairs’ opening remarks

J. Mark Gidley, White & Case, Washington, DC
Christine Siegwarth Meyer, NERA Economic Consulting, New York 

9.30: Keynote address

10.15: Pricing cases: what do they mean for the future of pharma?

The scrutiny of pricing in the pharmaceuticals sector has, if anything, become fiercer in 2018. How has this enforcement by the agencies and court decisions from private litigation affected the industry and its business practices?

Questions the panel are expected to discuss include:

  • What is the effect of industry consolidation on drug pricing?
  • How are the agencies evaluating the effect of mergers on short-term and longer-term pricing?
  • How has alleged collusion in the generic drugs market affected pricing, and how will those cases affect future enforcement?
  • How effective are “pay-for-delay” settlements in today’s industry?

Panellists:
Thomas Dillickrath, Deputy Chief Trial Counsel, Virginia
Chris Stomberg, NERA Economic Consulting, Washington, DC
Christopher W. Healy, Reed Smith, New York

11.30: Coffee break

12.00: Innovation: a double-edged sword?

Innovation is commonly accepted as beneficial for consumers and the market, but pharmaceutical companies have also been accused of using innovation and patents as an anti-competitive sword against potential competitors. How can companies understand what is ‘good’ and ‘bad’ innovation?

Questions the panel are expected to discuss include:

  • Is the pharmaceutical industry in need of more regulation - or less?
  • Is product hopping to extend patent life a clever tactic, or deleterious for the market?
  • How are method of use patents seen by authorities and courts?
  • What has been and will be the impact of alleged sham patent litigation?
  • How should innovation be considered in merger review in the pharma sector?

Moderator:
Kathleen Bradish, Cleary Gottlieb Steen & Hamilton, Washington, DC

Panellists:
David Emmanuelson, Global Antitrust Counsel, Intel, California
J. Mark Gidley, White & Case, Washington, DC
Kai Uwe-Kuhn, Professor of Economics, University of East Anglia, Norwich

13.15: Chairs’ closing remarks

J. Mark Gidley, White & Case, Washington, DC
Christine Siegwarth Meyer, NERA Economic Consulting, New York 

13.30: Networking lunch

Venue

2112 Pennsylvania Avenue, NW Washington, DC 20037

Ticket Prices

Private Practitioner
Type Price Until
Super Early $350 25 Jan 2019
Early $450 15 Feb  2019
Standard $550 28 Feb 2019

 

In-house/Government Representatives
Type Price
Standard $0